Reference:
U.S. Department of Health and Human Services. (2021). Fact sheet for recipients and caregivers: Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 12 years of age and older. Retrieved from www.cvdvaccine.com
Summary:
The Pfizer-BioNTech COVID-19 Vaccine is offered under emergency use authorization (EUA) to prevent COVID-19 in individuals aged 12 and older. This unapproved vaccine is administered in two doses, three weeks apart. While it may help prevent COVID-19, it does not guarantee protection for everyone. Recipients are advised to discuss any medical conditions, allergies, or previous reactions with their vaccination provider before receiving the vaccine. The vaccine has been shown to be effective in clinical trials, although potential risks include severe allergic reactions, myocarditis, and pericarditis. Side effects may occur but are generally mild. It is crucial to report any adverse reactions to healthcare providers. Individuals have the choice to receive the vaccine without impacting their standard medical care. The EUA for this vaccine remains valid during the COVID-19 pandemic, subject to review.